Login / Signup

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial.

Elisabetta PetracciEmanuela ScarpiAlessandro PassardiAnnibale BiggeriCarlo MilandriStefano VecchiaFabio GelsominoDavide TassinariStefano TamberiIlaria BernardiniCaterina AccetturaGiovanni Luca FrassinetiDino AmadoriOriana Nanni
Published in: Therapeutic advances in medical oncology (2020)
Our results seem to suggest that B confers a PFS advantage when administered in combination with second-line chemotherapy, which could help to improve current international guidelines on optimal sequential treatment strategies.
Keyphrases
  • metastatic colorectal cancer
  • randomized controlled trial
  • systematic review
  • locally advanced
  • squamous cell carcinoma
  • combination therapy
  • radiation therapy